^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Renal Cell Carcinoma
    Drug:Mvasi (bevacizumab-awwb) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    01/15/2018
    Excerpt:
    Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.
    Secondary therapy:
    recombinant interferon alfa-2a
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of…Metastatic renal cell carcinoma in combination with interferon-alfa
    Secondary therapy:
    alpha-interferon